|
The following projects represent some of the work being conducted in our labs and in the research facilities of our collaborative partners.
NON-VIRAL INFLUENZA VACCINE DEVELOPMENT
Molecular Express is developing a VesiVax® vaccine for influenza that incorporates the highly conserved ectodomain of the structural M2 protein...
More details...
|
GENITAL HERPES VACCINE DISCOVERY
Molecular Express has recently demonstrated that HSV2 VesiVax® vaccines targeted to selected epitopes from the gD viral envelope...
More details...
|
ASPERGILLUS VACCINE
Using the VesiVax® system, Molecular Express is constructing several vaccine candidates for testing in relevant animal models...
More details...
|
LIPOSOMAL ADJUVANT FOR VACCINE
Molecular Express has been developing a new model of immunization that is based on a flexible antigen delivery platform technology designed to...
More details...
|
LIPOSOMAL HIV VACCINE DEVELOPMENT
Using the VesiVax® platform technology, Molecular Express plans to develop a vaccine against HIV based on the relatively conserved...
More details...
|
|
